OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS).
Oxidative stress is caused by an imbalance between the production of reactive oxygen and a biological system’s ability to readily detoxify the reactive intermediates or easily repair the resulting damage.
OXIS presently holds the rights to 4 therapeutic classes of compounds in the treatment of oxidative stress, and has focused commercialization programs in clinical cardiovascular markers, including MPO (myeloperoxidase) and GPx (glutathione peroxidase), as well as the super-potent antioxidant, Ergothioneine, that is planned to be introduced as an over-the-counter nutraceutical supplement.
Oxis recently launched a human and veterinary sales and marketing campaign for ERGO and this scientific validation from the University of Cologne is expected to enhance the Company’s efforts in this area.
Ergothioneine considered as one of the most potent and effective in fighting oxidative stress, and is also the best antioxidant for therapeutics, cosmeceutical and even nutraceutical.
Oxidative stress is also caused by inflammation, exposure to cigarette smoke, pollution, UV light, radiation, certain drugs and other conditions and this stress is increases as we age.
We need antioxidants to fight such as rapid aging, heart disease, immune system decline, Cataracts, Arthritis, Cancer, and Diabetes.
To get to know about Oxis you can see their products in http://www.oxis.com, or join them on Oxis on facebook and Oxis on Twitter.
You must be logged in to post a comment.